AKEBIA THERAPEUTICS, INC. (AKBA)

0.97USD -0.87% (-0.01)

Over 1M: +7.1%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

0.85 0.9 0.95
7 Aug 12 Aug 17 Aug 20 Aug 25 Aug 28 Aug 2 Sep

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 58.8M Q3 '25 — Free Cash Flow: 28M Q4 '25 — Revenue: 57.6M Q4 '25 — Free Cash Flow: 31.1M Q1 '26 — Revenue: 53.5M Q1 '26 — Free Cash Flow: -21.3M Q2 '26 — Revenue: 49.1M Q2 '26 — Free Cash Flow: 2.4M -20M 0 20M 40M 60M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Gross Profit Free Cash Flow

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

6.0
ROIC —
OE margin 12.3%
Oper. margin 10.7%
Accruals -13.4%
Gross margin 79.6%
FCF margin 18.4%
OCF / EBIT 1.8×
OCF margin 19.0%
ROCE 12.4%
ROA -1.5%
ROE -21.4%

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

10.0
EV/EBIT 8.0×
EV/OE 7.0×
FCF yield 14.9%
P/C 1.7×
EV/Sales 0.86×
P/B 10.8×
Div. yield —
EV/GP —
Fwd P/E —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.2
RPO / sales 0.028×
RPO growth —
Segment HHI —

4 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

5.0
ND/EBITDA 0.43
Cash / Debt 2.1×
Debt payback 0.0 yr
F-score 6.0 pts
Quick ratio 1.3×
Debt / Eq 3.0×
Cash runway —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.8
Sales/sh Y/Y -11.8%
Sales Q/Q -21.4%
Shares change +21.9%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.